BELTSVILLE, Md. - NextCure, Inc. (NASDAQ:NXTC) announced Friday that data from its SIM0505 antibody drug conjugate Phase 1 dose escalation study is expected in the second quarter of 2026, while its ...
Company expands its ADC pipeline and patent estate for novel, differentiated ADCs New pipeline candidate AKTX-102 leverages Akari’s proprietary PH1 spliceosome payload and a novel antibody construct ...
TAMPA and LONDON, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company pioneering next-generation antibody drug conjugates (ADCs) powered by ...
New pipeline candidate AKTX-102 leverages Akari’s proprietary PH1 spliceosome payload and a novel antibody construct to address one of oncology’s most challenging and valuable solid tumor targets, ...
Company expands its ADC pipeline and patent estate for novel, differentiated ADCs New pipeline candidate AKTX-102 leverages Akari's proprietary PH1 spliceosome payload and a novel antibody construct ...
Somewhere along the way, we collectively decided that a fenced yard was the ultimate solution to a dog’s exercise and enrichment needs. Backyard = happiness. Problem solved. Except… no. When let out ...
SEATTLE, Wash., Jan. 15, 2026 (SEND2PRESS NEWSWIRE) — Third Sector Intelligence (3Si) today highlighted its Child Universal Success Platform (CUSP) Risk & Audit Analytics solution, a purpose-built ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results